RecruitingPhase 3NCT06559241

Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy(RECAST-MT)

Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy (RECAST-MT): A Multicenter, Randomized, Controlled, Open-label, Blinded Endpoint Trial


Sponsor

Capital Medical University

Enrollment

2,105 participants

Start Date

Sep 23, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

For patients with acute ischemic stroke caused by large vessel occlusion, endovascular thrombectomy has been demonstrated to be the most effective therapy, as approximately 90% of the occluded vessels can be recanalized. However, less than 50% of patients could achieve functional independence, and over 15% died 90 days after stroke. Although the mismatch of successful recanalization with poor prognosis can be attributed to many factors, the infarct core formed during thrombectomy and reperfusion injury after thrombectomy may be among the most important and effective neuroprotective strategies urgently needed. Remote ischemic conditioning (RIC) is a noninvasive strategy in which one or more cycles of brief and transient limb ischemia confer protection against prolonged and severe ischemia in distant organs. In the transient focal cerebral ischemia-reperfusion model, the application of remote ischemic conditioning before reperfusion or both before and after reperfusion reduces reperfusion injuries and the final infarct size. Because patients with acute ischemic stroke who are treated with endovascular thrombectomy can achieve a high rate of recanalization after focal ischemia, this patient population is akin to the model of transient focal cerebral ischemia-reperfusion. Furthermore, a pilot study has determined the safety and feasibility of remote ischemic conditioning in patients undergoing endovascular thrombectomy. However, whether remote ischemic conditioning could provide clinical benefits to patients with acute ischemic stroke who are treated with endovascular thrombectomy urgently needs investigations. This study aims to investigate the safety and efficacy of remote ischemic conditioning in improving functional outcomes of patients with acute ischemic stroke treated with endovascular thrombectomy and explore the effect of treatment duration on the treatment outcome of remote ischemic conditioning.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Age≥18 years;
  • Acute ischemic stroke due to large vessel occlusion in the anterior circulation that is not suitable for intravenous thrombolytic therapy, or has contraindications to intravenous thrombolytic therapy, or treated with intravenous thrombolytic therapy without recanalization;
  • Large vessel occlusion confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA), including the occlusion of the intracranial segment of the internal carotid artery (ICA) and M1 segment of the middle cerebral artery (MCA), is the cause of symptoms, and mechanical thrombectomy is planned within 24 hours from the time last known well;
  • Baseline score of the National Institutes of Health Stroke Scale (NIHSS) ≥ 6 points;
  • Patients or family members signed a written informed consent form.

Exclusion Criteria21

  • Imaging examination revealed the presence of multiple vascular supply areas of cerebral infarction (such as the simultaneous presence of infarction in both anterior and posterior circulation);
  • Absence of femoral artery pulsation, extremely difficult intravascular access, or extremely tortuous large vessels, which are expected to result in the inability to undergo timely endovascular treatment;
  • Difficult-to-control hypertension: continuous monitoring upon admission shows systolic blood pressure ≥180mmHg, or diastolic blood pressure ≥100mmHg;
  • Coma or lethargy patients (consciousness level score ≥2 in NIHSS);
  • Unable to obtain an accurate baseline NIHSS score;
  • Pre-stroke modified Rankin Scale (mRS) score >1;
  • Baseline ASPECTS score ≤5;
  • Presence of bleeding tendency, deficiency of coagulation factors, or oral anticoagulant therapy with INR > 3.0;
  • Baseline blood glucose <2.7mmol/L or >22.2mmol/L;
  • Baseline platelet count < 30*10\^9/L;
  • Severe known renal impairment defined as requiring dialysis (hemodialysis or peritoneal dialysis), or if known creatinine clearance rate <30mL/min;
  • Cranial CT or MRI shows intracranial hemorrhage;
  • Cranial CT or MRI shows midline deviation and significant occupying effect;
  • Clinical history, previous imaging examinations, or clinical judgment suggesting intracranial tumors, arteriovenous malformations, or intracranial arterial dissection;
  • History of head injury in the past 3 months;
  • History of life-threatening allergy to contrast agents, nickel, titanium metal, or their alloys;
  • Pregnancy, if women of childbearing age have a positive urinary or serum β-human chorionic gonadotropin (β-hCG) test or are breastfeeding;
  • The life expectancy of patients is less than 6 months, and they cannot be evaluated within 3 months;
  • Limb deformity, soft tissue injury, or other conditions that affect the implementation of distant ischemia adaptation therapy;
  • Participating in other ongoing clinical trials;
  • Other conditions that the investigators believe are not suitable for participation in this study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICE14-day remote ischemic conditioning

RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 14 days post-thrombectomy.

DEVICE30-day remote ischemic conditioning

RIC is a noninvasive therapy performed by an electric auto-control device with a cuff placed on the upper arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of the cuff on the upper arm. The procedure will be performed once before endovascular thrombectomy and twice daily for 30 days post-thrombectomy.

PROCEDUREEndovascular thrombectomy

Endovascular thrombectomy procedures are performed according to the guidelines to recanalize the occluded large vessel safely.

DRUGBest medical management

Best medical management is prescribed at the discretion of the treating physicians according to the guidelines.


Locations(56)

Suzhou Municipal Hospital of Anhui Province

Suzhou, Anhui, China

Taihe County People's Hospital

Taihe Chengguanzhen, Anhui, China

Tongling People's Hospital

Tongling, Anhui, China

Beijing Luhe Hospital affiliated to Capital Medical University

Beijing, Beijing Municipality, China

Beijing Fangshan District First Hospital

Beijing, Beijing Municipality, China

Fujian Provincial Hospital

Fuzhou, Fujian, China

Zhangzhou Municipal Hospital of Fujian Province

Zhangzhou, Fujian, China

Shenzhen Second People's Hospital

Shenzhen, Guangdong, China

South China Hospital Affiliated to Shenzhen University

Shenzhen, Guangdong, China

The Second Nanning People's Hospital

Nanning, Guangxi, China

Cangzhou Central Hospital

Cangzhou, Hebei, China

Army Medical University Noncommissioned Officer School Affiliated Hospital

Shijiazhuang, Hebei, China

Hebei General Hospital

Shijiazhuang, Hebei, China

The Hongda Hospital of Jiamusi University

Jiamusi, Heilongjiang, China

Xunxian People's Hospital

Hebi, Henan, China

Jiaozuo Coal Industry Group Co., Ltd. Central Hospital

Jiaozuo, Henan, China

Luoyang Yanshi People's Hospital

Luoyang, Henan, China

Nanyang Central Hospital

Nanyang, Henan, China

Henan Province People's Hospital

Zhengzhou, Henan, China

Xihua county people's hospital

Zhoukou, Henan, China

Huanggang Central hospital

Huanggang, Hubei, China

Huangshi central hospital

Huangshi, Hubei, China

Jingmen Central hospital

Jingmen, Hubei, China

Jingmen People's Hospital

Jingmen, Hubei, China

First People's Hospital of Tianmen

Tianmen, Hubei, China

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China

The Third People's Hospital of Hubei Province

Wuhan, Hubei, China

Yichang Central People's Hospital

Yichang, Hubei, China

the First People's Hospital of Changde

Changde, Hunan, China

The Third Xiangya Hospital of Central South University

Changsha, Hunan, China

the First People's Hospital of Chenzhou

Chenzhou, Hunan, China

The Central Hospital of Xiangtan

Xiangtan, Hunan, China

Inner Mongolia Autonomous Region People's Hospital

Hohhot, Inner Mongolia, China

The Fourth Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Anshan Changda Hospital

Anshan, Liaoning, China

Dalian Central Hospital

Dalian, Liaoning, China

The First Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, China

Shengli Oilfield Central Hospital

Dongying, Shandong, China

Jinan Third People's Hospital

Jinan, Shandong, China

Liaocheng People's Hospital

Liaocheng, Shandong, China

Liaocheng Third People's Hospital

Liaocheng, Shandong, China

The People's Hospital of Gaotang

Liaocheng, Shandong, China

Feixian People's Hospital

Linyi, Shandong, China

Yeda Hospital

Yantai, Shandong, China

Mianyang third people's hospital

Mianyang, Sichuan, China

Ya 'an People's Hospital

Ya'an, Sichuan, China

The Second Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Yueqing People's Hospital

Yueqing, Zhejiang, China

Beijing Chao-Yang Hospital

Beijing, China

Aerospace Central Hospital

Beijing, China

Xuanwu Hospital, Capital Medical University

Beijing, China

Beijing Fengtai You'anmen Hospital

Beijing, China

Beijing Red Cross Emergency Medical Center

Beijing, China

Beijing Daxing District People's Hospital

Beijing, China

Chongqing University Fuling Hospital

Chongqing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06559241


Related Trials